Tommy Li
Impact in
- Oncology top 10%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Pathology and Forensic Medicine top 10%
- Lymphoma Diagnosis and Treatment
Papers in
- Oncology 15
- CAR-T cell therapy research 14
- Cancer Immunotherapy and Biomarkers 3
- Colorectal Cancer Treatments and Studies 1
-
- Monoclonal and Polyclonal Antibodies Research 10
- Co-authors
- Dena DeMarco (3 shared papers)Roberto S Oliveri (3 shared papers)Brian Elliott (2 shared papers)Christopher Chiu (3 shared papers)Tahamtan Ahmadi (5 shared papers)Martin Hutchings (2 shared papers)Kim Linton (1 shared paper)Rogier Mous (1 shared paper)
- Journals
- Blood (6 papers)Clinical Pharmacology & Therapeutics (3 papers)Cancer Research (2 papers)The Lancet (1 paper)European Journal of Cancer (1 paper)
- Partner nations
- United StatesNetherlandsDenmark
In The Last Decade
Tommy Li
14 papers receiving 386 citations
Tommy Li's Hit Papers
Peers
Comparison fields: 5 of 40
- Oncology 338
- Pathology and Forensic Medicine 191
- Genetics 66
- Radiology, Nuclear Medicine and Imaging 101
- Immunology 78
Countries citing papers authored by Tommy Li
This map shows the geographic impact of Tommy Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tommy Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tommy Li more than expected).
Fields of papers citing papers by Tommy Li
This network shows the impact of papers produced by Tommy Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tommy Li. The network helps show where Tommy Li may publish in the future.
Co-authors
The 25 scholars most cited alongside Tommy Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study Hit paper breakdown → | 2021 | 212 |
| 2 | 2020 | 106 | |
| 3 | 2022 | 25 | |
| 4 | 2021 | 13 | |
| 5 | 2023 | 9 | |
| 6 | 2023 | 6 | |
| 7 | 2020 | 4 | |
| 8 | 2022 | 4 | |
| 9 | 2023 | 3 | |
| 10 | 2024 | 2 | |
| 11 | 2024 | 2 | |
| 12 | 2025 | 1 | |
| 13 | 2023 | 1 | |
| 14 | 2023 | 1 | |
| 15 | 2025 | 0 |
About Tommy Li
Tommy Li is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging, Immunology, Pathology and Forensic Medicine and Genetics, having authored 15 papers that have together received 389 indexed citations. Recurring topics across this work include CAR-T cell therapy research (14 papers), Monoclonal and Polyclonal Antibodies Research (10 papers), Biosimilars and Bioanalytical Methods (7 papers), Lymphoma Diagnosis and Treatment (4 papers), Cancer Immunotherapy and Biomarkers (3 papers), Chronic Lymphocytic Leukemia Research (2 papers), Colorectal Cancer Treatments and Studies (1 paper) and Neuroblastoma Research and Treatments (1 paper). The work is most often cited by research in Oncology (338 citations), Pathology and Forensic Medicine (191 citations), Genetics (66 citations), Radiology, Nuclear Medicine and Imaging (101 citations) and Immunology (78 citations). Tommy Li has collaborated with scholars based in United States, Netherlands and Denmark. Frequent co-authors include Dena DeMarco, Roberto S Oliveri, Brian Elliott, Christopher Chiu, Tahamtan Ahmadi, Martin Hutchings, Kim Linton, Rogier Mous, Anna Sureda and Ada Azaryan. Their work appears in journals such as Blood, Clinical Pharmacology & Therapeutics, Cancer Research, The Lancet and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.